<- Go Home
Greenbrook TMS Inc.
Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared neurostimulation therapy for the treatment of major depressive disorder and other mental health disorders. The company also offers Spravato, an esketamine nasal spray; and other treatment modalities for the treatment of depression and related psychiatric services. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.
Market Cap
$3.2M
Volume
893.6K
Cash and Equivalents
$3.3M
EBITDA
-$30.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.3M
Profit Margin
1.70%
52 Week High
$0.64
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
-0.01
Price / Earnings
-0.02
Price / Tangible Book Value
-0.01
Enterprise Value
$161.0M
Enterprise Value / EBITDA
-5.32
Operating Income
-$31.8M
Return on Equity
60.92%
Return on Assets
-27.89
Cash and Short Term Investments
$3.3M
Debt
$165.0M
Equity
-$127.6M
Revenue
$75.2M
Unlevered FCF
-$21.0M
Sector
Health Care Providers and Services
Category
N/A